Introduction
Several studies described an influence of brain nutrients-specifically glucose and cholesterol-on outcome in patients with acute ischemic stroke. High serum glucose levels are unanimously considered markers of adverse outcome [1] . Up to date, two studies have examined the potential influence of serum cholesterol levels (SCL) on outcome in patients with acute ischemic stroke; one described a better outcome in patients with higher admission SCL [2] , while the second reported a decreased mortality following acute ischemic stroke in patients taking lipid lowering agents at stroke onset [3] . The purpose of this study was to evaluate the hypothesis that SCL influence the clinical course of acute stroke patients. We therefore examined the relation between SCL and (1) severity of neurological deficit on admission, (2) neurological outcome at 3 months and (3) neurological recovery in patients with first-ever ischemic stroke.
Patients and Methods
Prospectively collected data from 889 consecutive patients with first ever acute ischemic stroke admitted in our neurological department between August 1997 and December 2004 were retrospectively analyzed for this study. Patients enrolled in therapeutic trials, patients who suffered a recurrent ischemic stroke (n=22) or patients who died (n=30) during the follow-up period were excluded from this study. Diagnostic work-up Cranial CT (CCT) was performed in all patients on admission. 12-lead ECG and ultrasound evaluation of the brain supplying arteries [4] were performed in all, and brain MRI, 24-h ECG monitoring and transthoracic or transesophageal (TEE) echocardiography in selected cases.
The following clinical characteristics were assessed: Age; sex; arterial hypertension defined by pre-admission history and medical records; diabetes mellitus defined either as fasting venous plasma glucose concentration of ≥7.0 mmol/l after an overnight fast on at least two separate occasions, or as venous plasma glucose concentration of ≥ 11.1 mmol/l following the ingestion of 75 g of oral glucose during the 2-h test; smoking; total venous SCL from blood drawn within 48 hours after symptom onset with the patient in supine position; severity of neurological deficit, using the National Institute of Health Stroke Scale (NIHSS), at presentation (NIHSS 0 ) and after three months (NIHSS 1 ). Stroke etiology was defined according to the Trial of Org 10172 in Acute Stroke Treatment (TOAST) classification [5] as (1) Since the relationship between ∆ NIHSS and SCL was the main interest of this study, latter variable was kept in the model, even if not significant.
Results
Data from 837 patients, 66% men, age 62±14 years (mean±SD, minimum 16, maximum 90 years) was analyzed. Arterial hypertension was found in 526 (63%) and diabetes mellitus in 128 (15%) patients. NIHSS 0 score was 6±5 (mean±SD; minimum 0, maximum 40). Etiology of stroke was atherothrombotic in 238 (28%), cardioembolic in 156 (19%), lacunar in 181 (22%), other determined etiology in 82 (10%) and undetermined in 210 (25%) patients. NIHSS 1 was 2.3±1.8 (mean±SD; minimum 0, maximum 22) and ∆ NIHSS 3.4±3 (mean±SD; minimum -7, maximum 28). Clinically insignificant correlations between SCL and NIHSS 0 (r= -0.13, p=0.0002), NIHSS 1 (r= -0.09, p=0.009; Figure 1 ) and Δ NIHSS (r=-0.1, p=0.03, all Pearson test) were evident.
Multivariate binary logistic regression analysis with backward elimination of nonsignificant predictors revealed smoking (p=0.005), stroke etiology (p=0.005) and NIHSS 0 (p<0.001) but not age (p=0.995), gender (p=0.79), arterial hypertension (p=0.4), diabetes mellitus (p=0.96) and SCL (p=0.89) as predictors for Δ NIHSS ≤ 0 or > 0 (Table 1) .
Discussion
A previous study demonstrated a worse outcome in patients with admission SCL < 6.5 mmol/l, as compared to remaining patients at one month follow-up [2] . The present study could not confirm this finding: even though the correlations between SCL and the clinical measures (NIHSS 0 , NIHSS 1 , Δ NIHSS ) were statistically significant, the low r-values suggest that this result is of no clinical relevance. The reason for the discrepancy between our results and those of the previous paper could be methodological differences, particularly concerning duration of followup (one month in the previous and three in our study) and dichotomization of SCL at 6.5 mmol/l.
It could be argued that our failure to reproduce the results of the former study was simply due to the lower number of enrolled patients. However, the results of our statistical analysis were clearcut and did not demonstrate trends for clinically relevant effects of SCL. We refrained from dichotomizing our data using a specific SCL value as cut-off point, as this statistical method is clearly inferior to the multivariate model applied.
In conclusion, our data suggest that SCL in patients with acute ischemic stroke are not associated with neurological deficit on admission, outcome or neurological recovery. 
